Dublin, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $1.6 Billion by 2030
The global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$587.6 Million in the year 2022, is projected to reach a revised size of US$1.6 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. Cytarabine, one of the segments analyzed in the report, is projected to record 15.6% CAGR and reach US$571.6 Million by the end of the analysis period. Growth in the Anthracycline Drugs segment is estimated at 14.5% CAGR for the next 8-year period. 
The U.S. Market is Estimated at $217.3 Million, While China is Forecast to Grow at 15.4% CAGR
The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$217.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$151 Million by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12% and 12.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.
What`s New?
- Special discussions on the global economic climate and market sentiment
- Coverage on global competitiveness and key competitor percentage market shares
- Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and trademarked research platform
- Complimentary updates for one year
- Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 356 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $587.6 Million |
| Forecasted Market Value (USD) by 2030 | $1600 Million |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
MARKET TRENDS & DRIVERS
- High Incidence and Prevalence Drive Market Growth
- Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
- Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
- Life Expectancy for Select Countries in Number of Years: 2019
- Advancements in Pharmacology & Molecular Biology to Promote AML Drug Development
- Recent Drug Approvals
- Rising Investments in AML Therapeutics R&D Augurs Well
- Changing Face of Combination Therapies Improve Outcomes for treated Secondary AML
- University of Texas' Combination Therapy Study Shines Light at the end of Tunnel for Acute Myeloid Leukemia
- Need for Better Treatments Entrenches Proteomics at Center of Acute Myeloid Leukemia Therapeutics R&D
- Antibody-Oriented Protein Microarrays
- AML - A Medical Challenge with High Relapse Rate
- Therapeutic Landscape for Refractory/Relapsed Acute Myeloid Leukemia
- Advances Related to FLT3 Inhibitors
- Gilteritinib to Set New Therapeutic Paradigm for Acute Myeloid Leukemia
- Novel Combination Therapies for Relapsed or Refractory AML
- Novel Therapies for Treatment of Pediatric Relapsed AML
- Immunotherapy Research for AML
- Monoclonal Antibody (Mylotarg) - A Promising Drug
- Chemotherapy Complications to Hinder the AML Market Growth
MARKET OVERVIEW
COVID-19 IMPACT AND THE LOOMING RECESSION
- COVID-19's Impact on Cancer Patients
- Making the Cancer Patient Survive the Lethal Covid-19 Wave
- Post-Covid-19 Complications to Affect Future Cancer Treatment
- The Evolving Model of Care - Virtual/ Telemedicine Consultations
- The Evolving Model of Care - Extending Care through Innovative Means
- Pandemic Causes Delays in Procedures and Treatment
- In-Office Cancer Patient Visits Decline amidst Pandemic
- Vaccine Availability Comforts Cancer Patients
COVID-19 IMPACT ON ACUTE MYELOID LEUKEMIA THERAPEUTICS
- Pandemic Caused Delays Impact AML Patients
- Pandemic Related Issues Affect Oncology Research
- Competition
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Acute Myeloid Leukemia (AML) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
LEUKEMIA - A DISEASE OF THE BONE MARROW
- A Prelude to Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia: Epidemiology
- Acute Myeloid Leukemia (AML) Types
- The FAB Classification of AML
- WHO AML Classification
- Etiology of AML
- AML Symptoms
GLOBAL MARKET OUTLOOK AND PROSPECTS
- Acute Myeloid Leukemia (AML) Therapeutics Market Primed for Massive Growth with Rising Patient Count & Promising Research Efforts
- Drug Development Efforts Set Pace for Global Market
- New Therapies Introduced in the Landscape
RECENT LAUNCHES IN THE AML MARKET
- North America Maintains Leadership Position in Global Market
- Chemotherapy: The Standard Mode of Treatment for AML Over the Years
- Emerging Drug Therapies/Targeted Therapies for Acute Myeloid Leukemia to Drive the Market
- FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid Leukemia Therapeutics Market
- Global FLT3 Inhibitors Market: Annual Sales in US$ Million for Years 2020 through 2027
EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA
- Chemotherapy
- AML Treatment
- Stem Cell Transplant for Acute Myeloid Leukemia (AML)
- Targeted Therapies Drive the Future of AML Market
ISOCITRATE DEHYDROGENASES (IDH)
- BCL-2 Inhibitor
- FLT3
- Hedgehog (Hh)
- Immunotherapy-Oriented Treatments
- Neurotransmitter Receptors
- Epigenetic Modulators
- Organelle-Directed Strategies
- New Formulations Using Existing Options
- Antibody-Drug Conjugate Therapy for Acute Leukemia
- Competitive Environment of AML Market
FOCUS ON SELECT PLAYERS(Total 112 Featured)
- Amgen, Inc.
- Astellas Pharma, Inc.
- AbbVie, Inc.
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Actinium Pharmaceuticals, Inc.
- Aptose Biosciences, Inc.
- Aprea Therapeutics
- Astex Pharmaceuticals, Inc.
- AB Science SA
- Aptevo Therapeutics
- Ascentage Pharma
- arGEN-X
- Accent Therapeutics
- Arcellx
- Amphivena Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/o695nn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
